ATE461214T1 - Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden - Google Patents

Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden

Info

Publication number: ATE461214T1
Authority: AT; Austria
Prior art keywords: tumour; present; relates; associated peptides; tumor
Prior art date: 2005-09-05

Application number

AT07007914T

Other languages

English (en)

Inventor

Joern Dengjel

Original Assignee

Immatics Biotechnologies Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-09-05

Filing date

2005-09-05

Publication date

2010-04-15

2005-09-05 Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh

2010-04-15 Application granted granted Critical

2010-04-15 Publication of ATE461214T1 publication Critical patent/ATE461214T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Toxicology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Biotechnology (AREA)
Cell Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Virology (AREA)
Developmental Biology & Embryology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT07007914T 2005-09-05 2005-09-05 Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden ATE461214T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP05019254A EP1760088B1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte Peptide, welche an unterschiedliche menschliche Leukozytenantigene der Klasse II binden

Publications (1)

Publication Number	Publication Date
ATE461214T1 true ATE461214T1 (de)	2010-04-15

Family

ID=35170099

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
AT07007914T ATE461214T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT07007915T ATE461215T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT05019254T ATE388164T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT06791838T ATE451388T1 (de)	2005-09-05	2006-09-05	Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
AT09011319T ATE532795T1 (de)	2005-09-05	2006-09-05	Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet

Family Applications After (4)

Application Number	Title	Priority Date	Filing Date
AT07007915T ATE461215T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT05019254T ATE388164T1 (de)	2005-09-05	2005-09-05	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
AT06791838T ATE451388T1 (de)	2005-09-05	2006-09-05	Tumorassoziierte peptide, die promiskuitiv an humane leukozytenantigen- (hla-) moleküle der klasse ii binden
AT09011319T ATE532795T1 (de)	2005-09-05	2006-09-05	Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet

Country Status (23)

Country	Link
US (6)	US10196432B2 (de)
EP (6)	EP1806358B1 (de)
JP (1)	JP5627180B2 (de)
KR (3)	KR101386355B1 (de)
CN (3)	CN103059104B (de)
AT (5)	ATE461214T1 (de)
AU (2)	AU2006289290B2 (de)
BR (1)	BRPI0615462A2 (de)
CA (2)	CA2621389C (de)
CY (5)	CY1107973T1 (de)
DE (4)	DE602005020047D1 (de)
DK (5)	DK1806359T3 (de)
EA (1)	EA013876B1 (de)
ES (5)	ES2302546T3 (de)
HK (1)	HK1220709A1 (de)
HR (2)	HRP20100128T1 (de)
NO (1)	NO340870B1 (de)
NZ (2)	NZ566104A (de)
PL (5)	PL1806358T3 (de)
PT (5)	PT1806358E (de)
SI (5)	SI1760088T1 (de)
UA (1)	UA98295C2 (de)
WO (1)	WO2007028574A2 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK1806359T3 (da) *	2005-09-05	2010-06-14	Immatics Biotechnologies Gmbh	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
US20090004213A1 (en) *	2007-03-26	2009-01-01	Immatics Biotechnologies Gmbh	Combination therapy using active immunotherapy
PL3042914T3 (pl)	2007-07-27	2019-01-31	Immatics Biotechnologies Gmbh	Nowe immunogenne epitopy do immunoterapii
CA2817054C (en)	2007-07-27	2017-02-28	Immatics Biotechnologies Gmbh	Composition of tumour-associated peptides and related anti-cancer vaccine
JP6008461B2 (ja)	2007-07-27	2016-10-19	イマティクスバイオテクノロジーズゲーエムベーハー	神経細胞性脳腫瘍に対する新規免疫療法
EP2192179B9 (de)	2007-08-20	2017-11-15	Oncotherapy Science, Inc.	Cdh3-peptid und dieses enthaltendes arzneimittel
US20100310640A1 (en)	2007-11-01	2010-12-09	Knutson Keith L	Hla-dr binding peptides and their uses
DK2105501T3 (da)	2008-03-27	2015-11-23	Immatics Biotechnologies Gmbh	Hidtil ukendt immunterapi mod neuronale tumorer og hjernetumorer
DK2113253T3 (da) *	2008-04-30	2010-07-19	Immatics Biotechnologies Gmbh	Ny sammensætning af tumorassocierede peptider, der bindes til humant leukocyt-antigen (HLA) klasse I eller II molekyler, til vaccinebrug
NO2119726T3 (de)	2008-05-14	2015-05-23
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
EP2172211B1 (de)	2008-10-01	2014-12-03	Immatics Biotechnologies GmbH	Zusammensetzung aus tumorassoziierten Peptiden und damit verbundene Antikrebsimpfung zur Behandlung von Glioblastoma (GBM) und anderen Krebsarten
BRPI1007443B8 (pt) *	2009-01-28	2021-07-27	Bio Preventive Medicine Corp	método para diagnosticar nefropatia diabética em um indivíduo, método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo, método para determinação do estágio da nefropatia diabética em um indivíduo, método para monitoramento do progresso da nefropatia diabética em um indivíduo, e método para avaliar a eficácia de um tratamento para nefropatia diabética em um indivíduo
US9023802B2 (en)	2009-12-14	2015-05-05	Immatics Biotechnologies Gmbh	HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof
GB201004551D0 (en) *	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201004575D0 (en)	2010-03-19	2010-05-05	Immatics Biotechnologies Gmbh	Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201009222D0 (en)	2010-06-02	2010-07-21	Immatics Biotechnologies Gmbh	Improved cancer therapy based on tumour associated antigens derived from cyclin D1
MX2013006758A (es)	2010-12-14	2013-08-01	Immatics Biotechnologies Gmbh	Peptidos de union a hla derivados de moleculas antigenicas asociadas a la prostata y metodos de uso de los mismos.
AU2012230780B2 (en) *	2011-03-23	2016-10-27	Fred Hutchinson Cancer Center	Method and compositions for cellular immunotherapy
CN110041403B (zh)	2013-08-05	2023-03-10	伊玛提克斯生物技术有限公司	针对多种肿瘤例如包括nsclc在内的肺癌的新型免疫疗法
TWI776192B (zh)	2013-08-05	2022-09-01	德商伊瑪提克斯生物科技有限公司	新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（四）
GB201319446D0 (en)	2013-11-04	2013-12-18	Immatics Biotechnologies Gmbh	Personalized immunotherapy against several neuronal and brain tumors
GB201408255D0 (en) *	2014-05-09	2014-06-25	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML)
HRP20191671T1 (hr)	2014-05-09	2019-12-13	Immatics Biotechnologies Gmbh	Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml)
GB201411037D0 (en)	2014-06-20	2014-08-06	Immatics Biotechnologies Gmbh	Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL)
KR102643923B1 (ko)	2014-12-23	2024-03-05	이매틱스 바이오테크놀로지스 게엠베하	간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합
GB201501017D0 (en)	2014-12-23	2015-03-04	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MD3388075T2 (ro)	2015-03-27	2023-10-31	Immatics Biotechnologies Gmbh	Noi peptide și combinații de peptide pentru utilizare în imunoterapia împotriva unor diverse tumori (SEQ ID 25 - MXRA5-003)
GB201505305D0 (en) *	2015-03-27	2015-05-13	Immatics Biotechnologies Gmbh	Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201505585D0 (en)	2015-03-31	2015-05-13	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
GB201507030D0 (en)	2015-04-24	2015-06-10	Immatics Biotechnologies Gmbh	Immunotherapy against lung cancers, in particular NSCLC
GB201507719D0 (en)	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
NL2014935B1 (en)	2015-06-08	2017-02-03	Applied Immune Tech Ltd	T cell receptor like antibodies having fine specificity.
CR20200525A (es) *	2015-06-19	2020-12-23	Immatics Biotechnologies Gmbh	NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA Y MÉTODOS PARA CREAR SOPORTES PARA EL USO CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2018-0040)
PE20230321A1 (es)	2015-07-01	2023-02-22	Immatics Biotechnologies Gmbh	Nuevos peptidos y nuevas combinaciones de peptidos para el uso en la inmunoterapia contra el cancer de ovario y otros tipos de cancer
GB201511546D0 (en)	2015-07-01	2015-08-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
KR102890065B1 (ko)	2015-07-06	2025-11-21	이매틱스 바이오테크놀로지스 게엠베하	식도암 및 기타 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합
MY189596A (en)	2015-07-15	2022-02-18	Immatics Biotechnologies Gmbh	A novel peptides for use in immunotherapy against epithelial ovarian cancer and other cancers
GB201513921D0 (en)	2015-08-05	2015-09-23	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers
UA125817C2 (uk)	2015-08-28	2022-06-15	Імматікс Біотекнолоджіс Гмбх	Пептид, придатний для лікування та/або діагностики раку
PH12022551111A1 (en)	2015-10-05	2023-08-23	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
MY196837A (en)	2015-12-11	2023-05-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against various cancers
BR112018012374A2 (pt)	2015-12-16	2018-12-04	Gritstone Oncology, Inc.	identificação, fabricação e uso de neoantígeno
GB201522667D0 (en) *	2015-12-22	2016-02-03	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers
GB201602918D0 (en)	2016-02-19	2016-04-06	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers
GB201603568D0 (en) *	2016-03-01	2016-04-13	Immatics Biotechnologies Gmbh	Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer
IL302705A (en)	2016-03-01	2023-07-01	Immatics Biotechnologies Gmbh	Peptides, combinations of peptides, cell-based drugs for use in immunotherapy against bladder cancer and other types of cancer
GB201603987D0 (en) *	2016-03-08	2016-04-20	Immatics Biotechnologies Gmbh	Uterine cancer treatments
GB201604458D0 (en)	2016-03-16	2016-04-27	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against cancers
KR20220163523A (ko) *	2016-03-31	2022-12-09	바이오엔테크 유에스 인크.	신생항원 및 이것의 사용 방법
CA3020162A1 (en)	2016-04-06	2017-10-12	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers
SG10202006117QA (en)	2016-04-21	2020-08-28	Immatics Biotechnologies Gmbh	Immunotherapy against melanoma and other cancers
EA201892333A1 (ru)	2016-04-21	2019-03-29	Имматикс Байотекнолоджиз Гмбх	Иммунотерапия меланомы и других видов рака
JP7075125B2 (ja)	2016-05-25	2022-05-25	イマティクスバイオテクノロジーズゲーエムベーハー	標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
RU2630647C1 (ru) *	2016-05-27	2017-09-11	Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства	ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
WO2017212072A1 (en)	2016-06-10	2017-12-14	Umc Utrecht Holding B.V.	Human leukocyte antigen restricted gamma delta t cell receptors and methods of use thereof
TW202304970A (zh)	2016-08-26	2023-02-01	德商英麥提克生物技術股份有限公司	用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架
DE102016123893A1 (de)	2016-12-08	2018-06-14	Immatics Biotechnologies Gmbh	T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (de)	2016-12-08	2024-04-17	Immatics Biotechnologies GmbH	T-zell-rezeptoren mit verbesserter paarung
AR110857A1 (es)	2017-01-27	2019-05-08	Immatics Biotechnologies Gmbh	Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer
WO2018138257A1 (en)	2017-01-27	2018-08-02	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
TW202325724A (zh)	2017-01-27	2023-07-01	德商英麥提克生物技術股份有限公司	用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物
EP3576767A4 (de) *	2017-02-06	2020-12-02	Academia Sinica	Rekombinante proteine und verwendungen davon
US10899819B2 (en)	2017-04-10	2021-01-26	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
US11427614B2 (en)	2017-04-10	2022-08-30	Immatics Biotechnologies Gmbh	Peptides and combination thereof for use in the immunotherapy against cancers
SG10202100326SA (en)	2017-04-10	2021-02-25	Immatics Biotechnologies Gmbh	Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
PE20191711A1 (es) *	2017-04-10	2019-11-28	Immatics Biotechnologies Gmbh	Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer
CR20210169A (es)	2017-07-07	2021-06-10	Immatics Biotechnologies Gmbh	NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO DE LA INMUNOTERAPIA CONTRA EL CÁNCER DE PULMÓN, INCLUYENDO EL NSCLC, EL SCLC Y OTROS CÁNCERES (Divisional 2020-0059)
WO2019007974A1 (en)	2017-07-07	2019-01-10	Immatics Biotechnologies Gmbh	NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS
ES2995057T3 (en)	2017-09-18	2025-02-05	S & P Ingredient Dev Llc	Low sodium salt substitute with potassium chloride
EP4576103A3 (de)	2017-10-10	2025-08-27	Gritstone bio, Inc.	Neoantigenidentifizierung mit hotspots
IL274799B2 (en)	2017-11-22	2025-05-01	Gritstone Bio Inc	Reducing junction epitope presentation for neoantigens
US11464800B2 (en)	2018-02-09	2022-10-11	Immatics US, Inc.	Methods for manufacturing T cells
DE102018108996B4 (de)	2018-02-09	2021-10-21	Immatics US, Inc.	Verfahren zur Herstellung autologer T-Zellen
DE102018107224A1 (de)	2018-02-21	2019-08-22	Immatics Biotechnologies Gmbh	Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
JP7480064B2 (ja) *	2018-02-27	2024-05-09	グリットストーンバイオインコーポレイテッド	パンアレルモデルによる新生抗原の特定方法
EP3539562A1 (de) *	2018-03-12	2019-09-18	Eberhard Karls Universität Tübingen Medizinische Fakultät	Immuntherapeutische peptide
TW202016131A (zh)	2018-05-16	2020-05-01	德商英麥提克生物技術股份有限公司	用於抗癌免疫治療的肽
US10925947B2 (en)	2018-06-29	2021-02-23	Immatics Biotechnologies Gmbh	A*03 restricted peptides for use in immunotherapy against cancers and related methods
TW202019955A (zh)	2018-07-31	2020-06-01	德商英麥提克生物技術股份有限公司	B*07 限制肽和肽組合的抗癌免疫治療和相關方法
TW202028224A (zh)	2018-09-17	2020-08-01	德商英麥提克生物技術股份有限公司	B*44限制肽在抗癌免疫治療的用途和相關方法
TW202024121A (zh)	2018-09-18	2020-07-01	德商英麥提克生物技術股份有限公司	A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法
TW202039535A (zh)	2018-12-18	2020-11-01	德商英麥提克生物技術股份有限公司	B*08限制肽和肽組合物抗癌免疫治療和相關方法
KR102215578B1 (ko) *	2019-03-28	2021-02-15	한국과학기술연구원	인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도
PH12021553042A1 (en)	2019-06-06	2023-09-11	Immatics Biotechnologies Gmbh	Sorting with counter selection using sequence similar peptides
CN110305209B (zh) *	2019-07-09	2022-09-13	福建医科大学附属第一医院	用于治疗恶性肿瘤的多肽及其作为疫苗的用途
EP3827840A1 (de) *	2019-11-29	2021-06-02	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	Teipp-peptid-variante und verwendungen davon
US11891427B2 (en)	2020-09-29	2024-02-06	Immatics Biotechnologies Gmbh	Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers
DE102020125457A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
DE102020125465A1 (de)	2020-09-29	2022-03-31	Immatics Biotechnologies Gmbh	Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten
TW202241925A (zh)	2021-01-15	2022-11-01	德商英麥提克生物技術股份有限公司	用於不同類型癌症免疫治療的ｈｌａ展示肽
CN120712104A (zh) *	2022-10-14	2025-09-26	广东天科雅生物医药科技有限公司	针对神经胶质瘤的肽疫苗及其用途
CN117720620B (zh) *	2023-12-13	2024-07-23	无锡市儿童医院	小分子多肽和其药物组合物、其制药用途

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8211999B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8258260B2 (en) *	1970-02-11	2012-09-04	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US8212000B2 (en) *	1970-02-11	2012-07-03	Immatics Biotechnologies Gmbh	Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules
US4440859A (en)	1977-05-27	1984-04-03	The Regents Of The University Of California	Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
GR66050B (de) *	1977-09-20	1981-01-14	Licinvest Ag
US4704362A (en)	1977-11-08	1987-11-03	Genentech, Inc.	Recombinant cloning vehicle microbial polypeptide expression
LU88258I2 (de)	1978-12-22	1994-02-03
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4678751A (en)	1981-09-25	1987-07-07	Genentech, Inc.	Hybrid human leukocyte interferons
US4766075A (en)	1982-07-14	1988-08-23	Genentech, Inc.	Human tissue plasminogen activator
US4582800A (en)	1982-07-12	1986-04-15	Hoffmann-La Roche Inc.	Novel vectors and method for controlling interferon expression
US4757006A (en)	1983-10-28	1988-07-12	Genetics Institute, Inc.	Human factor VIII:C gene and recombinant methods for production
US4677063A (en)	1985-05-02	1987-06-30	Cetus Corporation	Human tumor necrosis factor
US4810648A (en)	1986-01-08	1989-03-07	Rhone Poulenc Agrochimie	Haloarylnitrile degrading gene, its use, and cells containing the gene
US4810781A (en)	1987-01-15	1989-03-07	The George Washington University	Methods of preparing epitopes of tumor associated antigens
JPH07508403A (ja) *	1992-04-03	1995-09-21	ラ　ホヤ　キャンサー　リサーチ　ファウンデーション	デコリンフラグメントおよび細胞調節因子を阻害する方法
CA2142007C (en) *	1992-08-11	2007-10-30	Robert Glen Urban	Immunomodulatory peptides
CA2175380A1 (en) *	1993-10-29	1995-05-04	Lan Bo Chen	A novel tumor marker and novel method of isolating same
AUPM322393A0 (en)	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
JPH10506004A (ja)	1994-07-27	1998-06-16	ザカウンシルオブザクィーンズランドインスティテュートオブメディカルリサーチ	ポリエピトープワクチン
UY24367A1 (es) *	1995-11-23	2000-10-31	Boehringer Ingelheim Int	Vacunas contra tumores y procedimiento para su produccion
ES2203782T3 (es)	1996-01-17	2004-04-16	Imperial College Innovations Limited	Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
US6610821B1 (en) *	1996-07-12	2003-08-26	Mcgill University	Compounds and methods for modulating endothelial cell adhesion
US6046031A (en)	1997-01-21	2000-04-04	Human Genome Sciences, Inc.	Metalloproteinases
US6316213B1 (en)	1997-03-19	2001-11-13	The Board Of Trustees Of The University Of Arkansas	Methods for the early diagnosis of ovarian, breast and lung cancer
ES2245048T3 (es)	1997-10-15	2005-12-16	Pharis Biotec Gmbh	Factor de crecimiento derivado de cadherina y su uso.
DE19757250A1 (de) *	1997-12-22	1999-07-01	Forssmann Wolf Georg Prof Dr	Insulin-like growth factor binding protein und seine Verwendung
US6746852B1 (en) *	1998-05-08	2004-06-08	Osi Pharmaceuticals, Inc.	AGS proteins and nucleic acid molecules and uses thereof
DE19936563A1 (de)	1999-08-04	2001-02-08	Boehringer Ingelheim Int	Tumorassoziiertes Antigen
DE19938583A1 (de)	1999-08-18	2001-02-22	Buehler Ag	Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial
US20020081590A1 (en) *	2000-02-04	2002-06-27	Aeomica, Inc.	Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence
US7118853B2 (en) *	2000-07-26	2006-10-10	Applied Genomics, Inc.	Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
WO2002050103A2 (en)	2000-12-20	2002-06-27	Glaxosmithkline Biologicals S.A.	Tumour-related antigens
AU2002303219A1 (en)	2001-03-30	2002-10-15	Corixa Corporation	Compositions and methods for the therapy and diagnosis of cancer
US6867283B2 (en)	2001-05-16	2005-03-15	Technion Research & Development Foundation Ltd.	Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells
US7049413B2 (en) *	2001-05-18	2006-05-23	Ludwig Institute For Cancer Research	MAGE-A3 peptides presented by HLA class II molecules
US7705120B2 (en) *	2001-06-21	2010-04-27	Millennium Pharmaceuticals, Inc.	Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
DE60227974D1 (de) *	2001-08-13	2008-09-11	Dana Farber Cancer Inst Inc	Diagnostische tests auf periostinbasis
US6906036B2 (en) *	2001-08-16	2005-06-14	Kimberly-Clark Worldwide, Inc.	Anti-aging and wound healing compounds
WO2003030836A2 (en) *	2001-10-12	2003-04-17	Case Western Reserve University	Neuronal regeneration
WO2003068940A2 (en) *	2002-02-14	2003-08-21	Curagen Corporation	Complexes and methods of using same
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
AU2002368151A1 (en) *	2002-08-13	2004-02-25	Warner-Lambert Company Llc	Matrix metalloproteinase inhibitors and methods for identification of lead compounds
JP2006516089A (ja) *	2002-10-02	2006-06-22	ジェネンテック・インコーポレーテッド	腫瘍の診断と治療のための組成物と方法
WO2004110345A2 (en) *	2002-10-29	2004-12-23	Pharmacia Corporation	Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
KR20060013425A (ko) *	2003-05-29	2006-02-09	밀레니엄 파머슈티컬스 인코퍼레이티드	유방암의 확인, 평가, 예방 및 요법에 대한 조성물, 키트및 방법
EP1646648A2 (de) *	2003-07-15	2006-04-19	Genova Ltd.	Bei kardiovaskulären erkrankungen reduzierte sezernierte polypeptidspezies
EP1757940A1 (de)	2005-08-26	2007-02-28	Cézanne S.A.S.	In vitro Methode zur Diagnose und zum Monitoring von Nierenzellkarzinom unter Verwendung von MMP-7 als humoraler Biomarker für Nierenzellkarzinom
PT1760089E (pt) *	2005-09-05	2009-10-19	Immatics Biotechnologies Gmbh	Peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antigénio leucocitário humano (hla) e correspondente vacina anti-cancerígena
DK1806359T3 (da) *	2005-09-05	2010-06-14	Immatics Biotechnologies Gmbh	Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler
EP1795599A1 (de) *	2005-12-09	2007-06-13	Schuler, Gerold, Prof. Dr.	Verfahren zur Herstellung Antigen-spezifischer Effektor T-Zellen

2005
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es not_active Expired - Lifetime
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de not_active Expired - Lifetime
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 EP EP07007914A patent/EP1806358B1/de not_active Expired - Lifetime
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de not_active Expired - Lifetime
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 EP EP07007915A patent/EP1806359B1/de not_active Expired - Lifetime
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es not_active Expired - Lifetime
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 EP EP05019254A patent/EP1760088B1/de not_active Expired - Lifetime
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de not_active Expired - Lifetime
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es not_active Expired - Lifetime
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
2006
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en not_active Ceased
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 EP EP06791838A patent/EP1922335B1/de active Active
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active Expired - Fee Related
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active Expired - Fee Related
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 EP EP09011317A patent/EP2138509A1/de not_active Withdrawn
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 EP EP09011319A patent/EP2135878B1/de active Active
- 2006-09-05 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active Expired - Fee Related
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
2007
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown

Also Published As

Publication number	Publication date
US20080207520A1 (en)	2008-08-28
DK1806358T3 (da)	2010-06-28
PL1760088T3 (pl)	2008-10-31
PL1806359T3 (pl)	2010-08-31
EP1922335B1 (de)	2009-12-09
CA2621389C (en)	2016-07-19
ATE461215T1 (de)	2010-04-15
PT2135878E (pt)	2012-01-05
EP1806358A3 (de)	2007-10-03
DE602005005196D1 (de)	2008-04-17
BRPI0615462A2 (pt)	2011-05-17
CN105440119A (zh)	2016-03-30
HK1183678A1 (en)	2014-01-03
EP1760088A1 (de)	2007-03-07
EP1806359A1 (de)	2007-07-11
ATE532795T1 (de)	2011-11-15
US20080206218A1 (en)	2008-08-28
CA2621389A1 (en)	2007-03-15
EP1806358B1 (de)	2010-03-17
NO340870B1 (no)	2017-07-03
EP1760088B1 (de)	2008-03-05
PT1806358E (pt)	2010-05-28
KR20130019034A (ko)	2013-02-25
WO2007028574A3 (en)	2007-05-24
US7833969B2 (en)	2010-11-16
EP1806358A2 (de)	2007-07-11
ES2341295T3 (es)	2010-06-17
NO20081683L (no)	2008-04-04
WO2007028574A9 (en)	2008-05-02
US20160115212A1 (en)	2016-04-28
US7833970B2 (en)	2010-11-16
ES2341802T3 (es)	2010-06-28
EP1806359B1 (de)	2010-03-17
DK2135878T3 (da)	2012-02-27
ES2302546T3 (es)	2008-07-16
ATE388164T1 (de)	2008-03-15
PL1806358T3 (pl)	2010-08-31
SI1806359T1 (sl)	2010-06-30
KR101386790B1 (ko)	2014-04-21
DE602006011030D1 (de)	2010-01-21
CY1109849T1 (el)	2014-09-10
HRP20100128T1 (hr)	2010-04-30
KR101386355B1 (ko)	2014-04-17
ES2373907T3 (es)	2012-02-10
CY1112186T1 (el)	2015-12-09
SI1922335T1 (sl)	2010-04-30
DK1760088T3 (da)	2008-06-09
WO2007028574A2 (en)	2007-03-15
ATE451388T1 (de)	2009-12-15
EA200800677A1 (ru)	2008-08-29
UA98295C2 (ru)	2012-05-10
KR20130019033A (ko)	2013-02-25
PL1922335T3 (pl)	2010-05-31
DE602005020046D1 (de)	2010-04-29
AU2010236029A1 (en)	2010-11-18
US7807642B2 (en)	2010-10-05
JP2010502173A (ja)	2010-01-28
SI1806358T1 (sl)	2010-06-30
PT1760088E (pt)	2008-05-14
EA013876B1 (ru)	2010-08-30
US10196432B2 (en)	2019-02-05
PT1806359E (pt)	2010-05-25
CY1110187T1 (el)	2015-01-14
US20080206217A1 (en)	2008-08-28
CN103059104B (zh)	2015-10-28
DK1806359T3 (da)	2010-06-14
CN101287754A (zh)	2008-10-15
EP2135878A1 (de)	2009-12-23
AU2010236029B2 (en)	2012-06-28
NZ588813A (en)	2011-06-30
DK1922335T3 (da)	2010-04-19
AU2006289290A1 (en)	2007-03-15
US10618945B2 (en)	2020-04-14
PL2135878T3 (pl)	2012-06-29
EP1922335A2 (de)	2008-05-21
SI2135878T1 (sl)	2012-03-30
HK1220709A1 (zh)	2017-05-12
CN101287754B (zh)	2013-02-13
EP2138509A1 (de)	2009-12-30
CY1110051T1 (el)	2015-01-14
CY1107973T1 (el)	2013-09-04
DE602005005196T2 (de)	2008-06-26
NZ566104A (en)	2011-04-29
EP2135878B1 (de)	2011-11-09
CA2929252A1 (en)	2007-03-15
KR101386827B1 (ko)	2014-04-17
DE602005020047D1 (de)	2010-04-29
KR20080052643A (ko)	2008-06-11
HRP20110981T1 (hr)	2012-02-29
US20100040590A1 (en)	2010-02-18
PT1922335E (pt)	2010-03-03
JP5627180B2 (ja)	2014-11-19
US20080206216A1 (en)	2008-08-28
CN103059104A (zh)	2013-04-24
SI1760088T1 (sl)	2008-06-30
AU2006289290B2 (en)	2010-11-25
ES2337399T3 (es)	2010-04-23

Legal Events

Date

Code

Title

Description

2010-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1806358

Country of ref document: EP

Publication	Publication Date	Title
ATE461215T1 (de)	2010-04-15	Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden
EA200800676A1 (ru)	2008-08-29	Опухолеассоциированные пептиды, связывающиеся с молекулами человеческого лейкоцитарного антигена (hla) i или ii класса, и относящаяся к ним противораковая вакцина
PL1642905T3 (pl)	2009-04-30	Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy